Jubilant Pharmova has Arun Kumar Sharma as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the company for an interim period, effective October 1, 2025. He will serve in this role until the appointment of a new CFO is finalised.

The appointment was approved by the company’s Board of Directors at its meeting held on September 23, 2025, based on the recommendations of the Nomination, Remuneration and Compensation Committee and the Audit Committee. It has been made on an interim basis to ensure a smooth transition while the process of identifying and appointing a permanent CFO is underway.

Sharma is a strategic and result-driven financial leader with over three decades of progressive experience across corporate finance, global treasury, investor relations, risk management, financial restructuring, insurance, capex control, and business transformation. Throughout his career, he has played a pivotal role in driving sustainable growth, enhancing shareholder value, and upholding governance standards across large listed companies.

He has held various positions in Jubilant Bhartia Group, including CFO role in Jubilant Pharma Holdings Inc., USA for approximately 4 years, Jubilant Lifesciences (Chemical Business) for around 3 years, and Jubilant Pharmova for nearly 2 years (April 2021 – May 2023).

Formerly known as Jubilant Life Sciences, Jubilant Pharmova is a global integrated pharmaceutical company with a diversified portfolio spanning: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses.

In the Radiopharma segment, Jubilant Pharmova manufactures and supplies radiopharmaceuticals through a network of 46 radio-pharmacies in the US. Its Allergy Immunotherapy business produces allergenic extracts and venom products for the US and international markets, including Canada, Europe, and Australia.

Through its CDMO Sterile Injectables division, the company offers comprehensive manufacturing services such as sterile fill-finish injectables (liquid and lyophilized), ophthalmic products (liquids, ointments, and creams), and ampoules.

The CRDMO business includes Drug Discovery Services, delivered through two state-of-the-art research centres in Bangalore and Noida in India, as well as the CDMO-API operations engaged in manufacturing Active Pharmaceutical Ingredients (APIs).

Meanwhile, Jubilant Therapeutics, the Proprietary Novel Drugs arm, is focused on developing innovative therapies in oncology and autoimmune disorders.

The company operates six manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies.